On 1 November 2011, the international European research project EpiPGX (Epilepsy Pharmacogenomics: delivering biomarkers for clinical use) started, coordinated by the University College London.
EpiPGX is a unique project which brings together renowned scientists from various academic institutions and SMEs throughout Europe. The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs). The project will use genome-wide analyses, including next-generation sequencing, in large, well-phenotyped patient cohorts to identify genome-based biomarkers, to improve use of current antiepileptic drugs (AEDs) and identify new therapy targets. SMEs, which are central to this project, will be able to take the data forward for development of clinical tests.
On the following pages you will find more information about the group, the project and our dissemination activities as well as a contact form to get in touch with us.
Please note: The EpiPGX project funding by the EU has ended on 31st October 2015. This website is not being updated any longer but serves as an archive and information site.
The participants of the project are still contactable via their institutional e-mail addresses.